Compare Stocks → 4x Better than Bitcoin (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ISRNASDAQ:PPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsPPHVanEck Pharmaceutical ETF$90.89+1.1%$88.18$74.05▼$91.00$471.72M0.72132,492 shs453,729 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceISRIsoray0.00%0.00%0.00%0.00%0.00%PPHVanEck Pharmaceutical ETF+1.08%+1.51%+0.53%+11.78%+18.70%CBOE shift unlocks new weekend income strategy (Ad)You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationISRIsorayN/AN/AN/AN/AN/AN/AN/AN/APPHVanEck Pharmaceutical ETFN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceISRIsorayN/AN/AN/AN/APPHVanEck Pharmaceutical ETF0.00N/A$100.4010.46% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00PPHVanEck Pharmaceutical ETFN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/APPHVanEck Pharmaceutical ETFN/AN/A16.59∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthISRIsorayN/AN/AN/AN/AN/APPHVanEck Pharmaceutical ETF$1.701.87%N/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioISRIsorayN/A14.3813.99PPHVanEck Pharmaceutical ETFN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipISRIsoray11.32%PPHVanEck Pharmaceutical ETFN/AInsider OwnershipCompanyInsider OwnershipISRIsoray2.42%PPHVanEck Pharmaceutical ETFN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableISRIsorayN/A142.11 million138.67 millionNot OptionablePPHVanEck Pharmaceutical ETF147,0005.19 millionN/AOptionableISR, PRSM, HSN, IFM, and PPH HeadlinesSourceHeadlineShould You Invest in the VanEck Pharmaceutical ETF (PPH)?zacks.com - March 8 at 7:21 AMThe Top 3 ETFs to Buy in March 2024investorplace.com - March 7 at 1:43 PM11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yieldsmarkets.businessinsider.com - February 28 at 3:40 PMNavigate to Success With These 4 Pharma Stocks to Buystocknews.com - February 28 at 1:01 PMThe 3 Hottest Healthcare ETFs to Buy in 2024investorplace.com - February 26 at 2:12 PMPPH VanEck Pharmaceutical ETFseekingalpha.com - February 21 at 8:39 PMHealthcare dealmakers see increased M&A, valuations in 2024: KPMGmsn.com - February 20 at 7:16 AMPharma ETF (PPH) Hit a 52-Week Highzacks.com - February 19 at 9:50 AMBig Pharma earnings season in spotlight amid positive sentimentmsn.com - January 28 at 1:06 PM5 ETF Zones Scaling New Highs at the Start of 2024finance.yahoo.com - January 8 at 1:13 PMPfizer in 2024: What to expect?msn.com - December 29 at 1:39 PMGilead in 2024: What to expect?msn.com - December 28 at 1:41 PMETFs to buy and sell as the GLP-1 craze boomscnbc.com - December 6 at 9:53 AM10 Best Performing Healthcare ETFs in 2023uk.finance.yahoo.com - November 14 at 4:43 PMPharma to Farmers: My 3 Favorite “Essential” ETFs To Consider Adding To Your Portfoliomsn.com - November 6 at 1:27 PMPPH ETF Stock Price Historyinvesting.com - November 1 at 5:10 PMPPH: GLP-1 Companies And Large-Cap Value Pharma Make For A Compelling Portfoliomsn.com - October 29 at 7:35 AM3 Resilient Pharma Stocks to Buy This Weekstocknews.com - October 26 at 9:05 PMOzempic craze drives big flows into pharmaceutical, Danish fundsmsn.com - October 25 at 12:42 PMEli Lilly, Novo among notable decliners in pharma weaknessseekingalpha.com - October 19 at 11:42 PMWhich of these 3 Pharma Stocks Should You Buy, Hold or Sell?stocknews.com - September 15 at 5:09 PMWhy is big pharma unmoved despite Medicare pricing threat?msn.com - September 3 at 3:24 PMPharma ETF (PPH) Hit a 52-Week Highau.news.yahoo.com - August 11 at 12:54 AMPPH - VanEck Pharmaceutical ETFfinance.yahoo.com - July 6 at 8:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIsorayNYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.VanEck Pharmaceutical ETFNASDAQ:PPHThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.